Research and Markets: The Chronic Obstructive Pulmonary Disorder Therapeutics Market Is Dominated By Glaxosmithkline and Boehringer Ingelheim
Posted on: Wednesday, 12 July 2006, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c39367) has announced the addition of Chronic Obstructive Pulmonary Disorder Therapeutics to their offering.
Often under-diagnosed and under-treated, chronic obstructive pulmonary disease (COPD) is usually not diagnosed in patients until they incur significant lung damage. With approximately 15 to 20% of all smokers eventually developing COPD, there are over 26 million patients worldwide who suffer from the disease, yet, only about 600,000 are diagnosed each year. It is estimated that less than half of Americans with lung function impairment have been properly diagnosed. Primary care physicians are being encouraged to routinely perform spirometry tests on smokers older than 45 years, which will increase diagnosis rates and drive market growth through 2010. Recently released bronchodilators Advair (salmeterol/fluticasone) and Spiriva (tiotropium bromide) have improved the standard of care for COPD. While most therapeutics emerging by 2010 are either reformulations of current drugs or products currently marketed for asthma, there are two, cilomilast (Ariflo) and roflumilast (Daxas), that comprise a novel class of phosphodiesterase 4 (PDE 4) inhibitors. These drugs offer oral tablet formulations, once or twice daily dosing, and both inflammatory and bronchodilator properties, and are expected to change the standard of care and significantly drive market growth. The COPD market is, which hold 84% of the market as of 2005. Although these players will remain the leaders in 2010, they will lose some market share to ALTANA Pharma, AstraZeneca, Sepracor, and Pfizer.
Topics Include:
I. Executive Summary
II. Objectives and Methodology
III. Chronic Obstructive Pulmonary Disease Overview
IV. Epidemiology
V. Current COPD Treatments
VI. Emerging Therapeutics
VII. Physician Insights
VIII. COPD Therapeutics Market
IX. Challenges and Strategic Options
Appendix
Companies Mentioned:
- ALTANA AG - AstraZeneca - Boehringer Ingelheim GmbH - GlaxoSmithKline - Merck KGaA - Novartis AG - Ono Pharmaceutical Co. Ltd - Pfizer - Provalis - Sanofi-Aventis - Schering-Plough - Sepracor - Tanabe Seiyaku
For more information visit http://www.researchandmarkets.com/reports/c39367
Source: Business Wire
Related Articles
- An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market
- Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Chronic Obstructive Pulmonary Disease
- Dallas-Fort Worth Business Group on Health Studies Impact of Chronic Obstructive Pulmonary Disease on Area Employees
- The Book 'Managing Chronic Obstructive Pulmonary Disease' Provides Insight into the Management of COPD at Home and in Hospital; Including Drug Treatments, Oxygen Therapy, and Non-Invasive Ventilation is Discussed
- Increasing Patient Population Ensuring the Growth of the U.S. Chronic Obstructive Pulmonary Disease (COPD) Market
- Update in Chronic Obstructive Pulmonary Disease 2005
- Medivir: Advances in Chronic Obstructive Pulmonary Disease (COPD) Research Program
- Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease
- Therapeutic Inhibition of Matrix Metalloproteinases for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Pharmacological Approaches to Stable Chronic Obstructive Pulmonary Disease
 |
 |
User Comments (0)
RSS Feeds